FDA Approves First Trivalent Influenza Vaccine Made Using Recombinant Technology

The FDA's recent approval of a trivalent seasonal influenza vaccine made using novel manufacturing technology marks a significant milestone in the ongoing battle against this life-threatening illness. According to a Jan. 16 FDA release, Flublok, which is approved for use in adults ages 18-49, does not rely on the traditional method of growing the targeted influenza virus strains in chicken eggs and, thus, can be produced more rapidly than current vaccines.
Source: AAFP Health of the Public - Category: Primary Care Source Type: news